Evidence map›Paper›PMID 40654991›Full record

ArticlebioRxiv : the preprint server for biology2025

Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis.

Jooho Chung, Mounica Vallurupalli, Sarah Noel, Gail Schor, YuhJong Liu, Celeste Nobrega, Jonathan J Perera, Ewa Wrona, Margaret Hu, Yunkang Lin and 24 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Jooho ChungBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Mounica VallurupalliBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.ORCID 0000-0002-1995-5283
Sarah NoelBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Gail SchorBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
YuhJong LiuBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Celeste NobregaBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Jonathan J PereraBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Ewa WronaBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Margaret HuBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Yunkang LinBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
David W WuBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Maria SaberiBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Ilario ScapozzaBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Aidan CruickshankBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Elliot C WoodsBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Cun Lan ChuongBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Filippo BirocchiKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School; Charlestown, MA, USA.
Ashwin V KammulaBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Omar I AvilaBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Mustafa KocakBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
John G DoenchBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Dean ProcterBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Lindsey ThorntonDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA USA.
Andrew M BrunnerKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School; Charlestown, MA, USA.
Eric WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA USA.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA USA.
Jacqueline S GarciaDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA USA.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA USA.
Russell W JenkinsBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Marcela V MausKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School; Charlestown, MA, USA.
Timothy A GraubertKrantz Family Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School; Charlestown, MA, USA.
Kathleen B YatesBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Todd R GolubBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.
Robert T MangusoBroad Institute of Harvard and Massachusetts Institute of Technology; Cambridge, MA USA.

Funding

Physician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M
Training Program in Molecular HematologyT32HL116324 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI NANCY BERLINER · 2013 to 2026
$7.4M
Making cancer precision medicine real: bottlenecks and opportunitiesR35CA242457 · NCI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R. · 2019 to 2025
$6.9M
NCI NIH HHS R35 CA242457NCI NIH HHS T32 CA009172NHLBI NIH HHS T32 HL116324
6 · The paper itself

Abstract

Macrophages in the tumor microenvironment exert potent anti-tumorigenic activity through phagocytosis. Yet therapeutics that enhance macrophage phagocytosis have not improved outcomes in clinical trials for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). To systematically identify regulators of phagocytosis, we performed genome-scale CRISPR knockout screens in human leukemia cells co-cultured with human monocyte-derived macrophages. Surprisingly, we found that whereas the classic "don't eat me" signal CD47 inhibited mouse macrophages, it did not inhibit phagocytosis by human macrophages. In contrast, the O-linked glycosylation and sialylation pathways were strong negative regulators of phagocytosis. In AML, the cell surface O-linked glycoprotein CD43 was the major effector of the O-linked glycosylation and sialylation pathways. Genetic deletion or antibody blockade of CD43 enhanced macrophage phagocytosis. This work highlights the importance of using human platforms to identify immune checkpoints, and nominates CD43 as a glyco-immune regulator of human macrophage phagocytosis.

Identifiers

PMID40654991
PMCPMC12247861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.